Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06463587 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
- 20
- Study locations
NCT06463587: Recruiting Phase 3 study of Generalized Myasthenia Gravis, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.
NCT06463587 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. The registered enrollment target is 264 participants, above the 121-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06463587, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cladribine Low Dose
- DRUG Cladribine High Dose
Study Locations (20)
Florida
- Neurology of Central Florida Research Center, LLC - Altamonte Springs
- SFM Clinical Research, LLC - Boca Raton
- University of Florida Health Science Center - 300120311 - Jacksonville
- Neurology Associates, P. A. - Maitland
- University of South Florida - PARENT - PARENT - Tampa
Texas
- Baylor Scott & White Research Institute - Baylor Scott & White Research Institute - Dallas
- ANESC Research - El Paso
- Baylor Scott & White Neurology - McKinney - McKinney
North Carolina
- UNC Hospitals - PARENT - Chapel Hill
- Atrium Health Wake Forest Baptist - Winston-Salem
Arizona
- Arizona Neuroscience Research, LLC - Phoenix
Colorado
- Advanced Neurosciences Research LLC - Longmont
District of Columbia
- The George Washington University Medical Faculty Associates Foggy Bottom South Pavilion - Washington D.C.
Kansas
- University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN) - Kansas City
Ohio
- Miami Valley Hospital South - Centerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2030-08-19 |
| Phase | Phase 3 |
Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany4 total trials
What NCT06463587 shows while recruiting
NCT06463587 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, above the 121-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (118% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06463587 names 20 study sites across 13 states, led by Florida, Texas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06463587 about?
NCT06463587 is a clinical study titled "Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)". The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of or...
What is the current status of trial NCT06463587?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2024-06-25. Estimated completion is 2030-08-19.
What conditions does trial NCT06463587 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06463587?
The interventions under investigation include: Placebo (OTHER), Cladribine Low Dose (DRUG), Cladribine High Dose (DRUG).
Who is sponsoring clinical trial NCT06463587?
This trial is sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06463587 being conducted?
This trial has 20 study locations across Arizona, Colorado, District of Columbia, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06463587's enrollment target sits among peer trials
264 3rd of 26 higher than 24 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI